IDO was upregulated in breast cancer-derived MDSCs via IL-6-triggered STAT-3 activation, which activated the non-canonical NFκB pathway resulting in enhanced transcriptional activity of the IDO promoter (56). Here, IDO1 is linked to breast carcinoma.